Peritoneal fluid penetration of tigecycline

Annals of Pharmacotherapy

Volumn 40, Issue 11, 2006, Pages 2064-2067

  Scheetz, Marc H ^a   Reddy, Pavani ^b   Nicolau, David P ^c,d   Noskin, Gary A ^b   Postelnick, Michael J ^a   Stosor, Valentina ^b   Zembower, Teresa R ^b  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Center for Anti Infective Research and Development   (United States)

^d HARTFORD HOSPITAL   (United States)

Author keywords

Peritoneal penetration; Tigecycline

Indexed keywords

CILASTATIN PLUS IMIPENEM; COLISTIMETHATE; HYPERTENSIVE FACTOR; LINEZOLID; PREDNISONE; TIGECYCLINE; TSUKUBAENOLIDE;

ACINETOBACTER BAUMANNII; ADULT; ANTIBIOTIC THERAPY; ARTICLE; ARTIFICIAL VENTILATION; ASCITES FLUID; CADAVER KIDNEY; CASE REPORT; CLINICAL FEATURE; DEATH; DISEASE SEVERITY; DRUG PENETRATION; DRUG PERITONEAL FLUID LEVEL; ENTEROCOCCUS FAECIUM; GRAFT REJECTION; HEMOFILTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; KLEBSIELLA PNEUMONIAE; LETHARGY; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; PERITONITIS; PRIORITY JOURNAL; SEPSIS; SUPERINFECTION; SYMPTOM; TRACHEOSTOMY; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; ASCITIC FLUID; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FATAL OUTCOME; HUMANS; MALE; MINOCYCLINE; PERMEABILITY;

EID: 33750978173     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H229     Document Type: Article

References (12)

1. Product information. Tygacil (tygecycline). Philadelphia, PA: Wyeth Pharmaceuticals, November 2005.
2. Darling IM, Cirincione BB, Owen JS. Noncompartmental pharmacokinetics (PK) of tigecycline in phase 3 studies of patients with complicated skin and skin-structure (cSSSI) and intra-abdominal infections (cIAI). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, December 16-19, 2005.
3. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41(suppl 5):S354-67.
4. Clinical and Laboratory Standards Institute/National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, 15th informational supplement. CLSI/NCCLS document M100-S15 [ISBN 1-56238-556-9]. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
5. Li C, Sutherland CA, Nightingale CH, Nicolau DP. Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2004;811:225-9.
6. National Committee for Clinical Laboratory Standards. Approved Guideline M26-A. Methods for determining bactericidal activity of antimicrobial agents. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.
7. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152 288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother 2000;44:943-9.
8. Meagher A, Passarell J, Cirincione B, et al. Exposure-response analysis of the efficacy of tigecycline in patients with complicated skin and skin-structure infections (poster 1184). Presented at: 15th European Congress of Clinical Microbiology and Infectious Diseases. Copenhagen, Denmark, April 2-5, 2005.
9. Passarell J, Liolios K, Meagher A, et al. Exposure-response analysis of the efficacy of tigecycline (T) in patients with complicated intra-abdominal infections (cIAI). Presented at: 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, December 16-19, 2005.
10. Ong CT, Babalola CP, Nightingale CH, Nicolau DP. Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 2005;56:498-501.
11. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32.
12. Troy SM, Muralidharan G, Micalizzi M, Mojavarian P, Salacinski L, Raible D. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936) (abstract A-22). Presented at: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 14-17, 2003.